TAL1/SCL is a hematopoietic-specific oncogene and its activity is regulated by associated transcriptional co-activators and corepressors. Dysregulation of TAL1 activity has been associated with T-cell leukemogenesis. However, it remains unclear how the interactions between TAL1 and corepressors versus co-activators are properly regulated. Here, we reported that protein kinase A (PKA)-mediated phosphorylation regulates TAL1 interaction with the lysine-specific demethylase (LSD1) that removes methyl group from methylated Lys 4 on histone H3 tails. Phosphorylation of serine 172 in TAL1 specifically destabilizes the TAL1 --LSD1 interaction leading to promoter H3K4 hypermethylation and activation of target genes that have been suppressed in normal and malignant hematopoiesis. Knockdown of TAL1 or LSD1 led to a derepression of the TAL1 target genes in T-cell acute lymphoblast leukemia (T-ALL) Jurkat cells, which is accompanied by elevating promoter H3K4 methylation. Similarly, treatment of PKA activator forskolin resulted in derepression of target genes by reducing its interaction with LSD1 while PKA inhibitor H89 represses them by suppressing H3K4 methylation levels. Consistent with the dual roles of TAL1 in transcription, TAL1-associated LSD1 is decreased while recruitment of hSET1 is increased at the TAL1 targets during erythroid differentiation. This process is accompanied by a dramatic increase in H3K4 methylation. Thus, our data revealed a novel interplay between PKA phosphorylation and TAL1-mediated epigenetic regulation that regulates hematopoietic transcription and differentiation programs during hematopoiesis and leukemogenesis.
INTRODUCTION
TAL1/SCL (hereafter referred as TAL1) is a hematopoietic-specific member of the basic Helix-Loop-Helix family of transcription factors important for the development of all hematopoietic lineages and pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL).
1 --5 TAL1 heterodimerizes with ubiquitously expressed E2A/HEB proteins and binds a hexanucleotide sequence CANNTG termed E box to act as a regulator of transcription during hematopoiesis. TAL1 is required for specification and self-renewal of hematopoietic stem cells (HSCs), as well as for terminal differentiation of erythrocytes. 6, 7 It is believed that TAL1 contributes mainly to transcriptional repression in early developmental stages and is then converted to an activator in complex with other erythroid-specific transcription factors, such as GATA-1, LMO2 and LDB1, to activate erythroid-specific transcription programs during differentiation. 8, 9 Several studies have shown that TAL1 could function either as a transcriptional activator or as a repressor in a context-dependent manner. TAL1 represses transcription by recruiting ETO2, mSin3A, HDAC1/2, or lysinespecific demethylase (LSD1). In contrast, it potentiates transcription by interacting with p300 and p300/CBP-associated factor. 10 --16 Many of the TAL1-associated proteins possess intrinsic histone modification activities, thereby, altering enhancer/promoter chromatin structure and modulating the recruitment of RNA Pol II basal transcription machinery. In addition, there is another layer of regulation of TAL1 protein. Several threonine (Thr) and serine (Ser) residues of TAL1 can be phosphorylated by protein kinase B (Akt), mitogen activated protein kinase and protein kinase A (PKA). 17 --20 In particular, serine 172 is phosphorylated in vitro and in vivo by PKA. 18 Phosphorylation of this residue affects TAL1 targetdependent DNA recognition, therefore, potentially discriminating the DNA binding site selection during differentiation. 18 The phosphorylation of TAL1 regulates its DNA binding and transcriptional activities, 17, 19 suggesting that phosphorylation may dictate TAL1's ability to associate with transcriptional corepressors and co-activators. 21 In T-cell leukemia, TAL1 activation has been frequently associated with this T-cell neoplastic disease. 22, 23 Ectopic expression of TAL1 in T cells led to the development of leukemia and lymphoma in mice. 24 --26 Furthermore, the gene expression profiling analysis of TAL1-induced preleukemic thymocytes showed that aberrant activation of TAL1 in T cells results in the repression of many more genes than genes being activated, 27 suggesting that TAL1-mediated transcriptional repression has a critical role in T-cell leukemogenesis. Among them, pre-TCRa (pTa) and CD4, which are critical for T-cell development, 27, 28 as well as p16INK4A and p21, two important cellcycle regulators, are repressed by TAL1 in T-cell leukemia. 15,29 --31 Consistent with these findings, it has been shown that TAL1 prevents erythroid progenitor differentiation by recruiting histone demethylase LSD1 and inhibits the TAL1 target genes required for differentiation. 13 Interestingly, TAL1 decreases its interaction with LSD1 during differentiation of erythroid cells and is switched to a transcriptional activator to activate erythroid-specific p4.2 gene expression. 13 Apparently, the dynamic regulation of TAL1 and its associated coregulators may determine the onset of the hematopoietic differentiation program. However, it remains unknown how TAL1/LSD1 interaction is regulated during hematopoiesis. During hematopoiesis, pluripotent HSCs are associated with both H3K4me3 and H3K27me3 to form so-called 'bivalent domains' that facilitate differentiation into specific lineages by changing the relative level of specific modification and allow lineage-specific genes to be rapidly transcribed or vice versa. 32 --34 LSD1 is the first identified histone lysine-specific demethylase involved in removing monomethylated or dimethylated H3K4. 35 As a putative transcriptional repressor, LSD1 associates with multiple corepressor complexes including COREST and NURD complexes. 36 --38 Histone deacetylase activities of these complexes facilitate the LSD1 enzymatic activity on the chromatin template and therefore, enhance its repressive function. 39 LSD1 regulates a variety of target genes that are required for cell survival, growth and differentiation through its ability to modulate promoter chromatin structure. 38, 40 Dysregulation of LSD1 function has been associated with genome instability and tumor metastasis. 37, 40, 41 Interestingly, knockdown (KD) of LSD1 in hematopoietic progenitors impairs differentiation of multiple hematopoietic lineages indicating that LSD1 has a critical role in hematopoiesis. 13, 42 To understand the detailed mechanism that regulates TAL1-associated coregulator complexes and how the dysregulation of this process contributes to T-cell leukemia, we investigated the underlying molecular mechanism that regulates the TAL1 and LSD1 interaction. We report here that the interaction between TAL1 and LSD1 is modulated by a PKA-mediated serine 172 phosphorylation located at the LSD1-interacting domain of TAL1. Phosphorylation mediated dynamic recruitment of LSD1 complex modulates TAL1-directed transcription of target genes that are essential for hematopoietic progenitor differentiation and T-cell development. Treatment of the PKA activator forskolin stimulates the expression of the TAL1 target genes by reducing its interaction with LSD1 while PKA inhibitor H89 further inhibits the TAL1 targets by suppressing promoter H3K4 methylation levels. Thus, our results suggest that the dynamic regulation of TAL1 and its associated histone demethylase LSD1 by PKA-mediated phosphorylation controls the transcription of the TAL1 target genes via modulating the promoter H3K4 methylation.
RESULTS
PKA-mediated serine 172 phosphorylation destabilizes the TAL1 and LSD1 interaction We reported recently that TAL1 dynamically interacts with histone demethylase LSD1 to negatively regulate TAL1-dependent transcription during erythroid differentiation. 13 To further understand the molecular mechanism underlying the regulation of the TAL1 --LSD1 interaction during hematopoiesis, we determined the domain of TAL1 required for LSD1 interaction. TAL1 directly interacts with LSD1, and the interacting domain encompasses amino acids (aa) 142 --185 proximal to the basic Helix-Loop-Helix domain (Figures 1a and b) , 13 which contains a serine 172 residue that can be phosphorylated by PKA (Figure 1a) . 18 To test whether serine 172 phosphorylation is important for TAL1 interaction with LSD1, the GST --TAL1 fusion mutants that delete the LSD1-interacting domain encompassing aa 142 --185, mutate serine 172 to aspartic acid (D), or change serine 172 to alanine (A) were conjugated with glutathione-sepharose beads and incubated with [
35 S]methionine-labeled LSD1 (Figure 1a ). TAL1 S172A that mimicked unphosphorylated TAL1 interacts strongly with LSD1 (Figure 1b , right) while TAL1
D142À185 that deleted the LSD1-interacting domain (Figure 1b , left) or TAL1 S172D that mimicked phosphorylated TAL1 (Figure 1b , right) completely loses its interaction with LSD1 (Figure 1b) , suggesting that the ser172 of TAL1 has an important role in regulating TAL1 interaction with LSD1.
It has been reported that ser172 of TAL1 can be phosphorylated by PKA in vitro and in vivo. 18 To test whether ser172 of TAL1 is phosphorylated by PKA and whether PKA-mediated phosphorylation alters the TAL1 and LSD1 interaction, we carried out in-vitro phosphorylation assay using purified GST --TAL1 fusion protein or the corresponding TAL1 fusion with a ser172 to Ala substitution (GST --TAL1 S172A ) as substrate. Compared with GST alone control, GST --TAL1 fusion protein was strongly phosphorylated by PKA 
D142À185
were precipitated with anti-Flag conjugated beads and analyzed by western blot with LSD1 antibody (Top) and Flag antibody (Bottom).
( Figure 1c) . Substitution of ser172 to Ala dramatically reduced the PKA-mediated phosphorylation (Figure 1c ), indicating that ser172 in TAL1 is a major target of PKA. In addition, the LSD1-interacting domain of TAL1 (GST --TAL1 142 --185 ) was also strongly phosphorylated ( Figure 1c ). Having demonstrated that ser172 of TAL1 is indeed phosphorylated by PKA, we then asked whether phosphorylation of ser172 by PKA altered the interaction between TAL1 and LSD1. To test this hypothesis, the fusion protein containing wild-type (WT) TAL1 (GST --TAL1), the LSD1-interacting domain of TAL1 (GST --TAL1 142 --185 ) or the ser172 to Ala substitution mutant (GST --TAL1 S172A ) was first phosphorylated in the presence or absence of PKA catalytic subunit, and then incubated with the purified LSD1. Phosphorylation of the LSD1-interacting domain of TAL1 or WT TAL1 completely lost its interaction with LSD1 (Figure 1d , left; Supplementary Figure S1A ), while incubation of GST --TAL1 S172A with or without PKA catalytic subunit did not affect TAL1's interaction with LSD1 (Figure 1d , right). Collectively, these results demonstrate that phosphorylation of serine 172 of TAL1 destabilizes its interaction with LSD1.
Furthermore, to test whether phosphorylation of ser172 affects the TAL1 and LSD1 interaction in vivo, we stably expressed Flagtagged TAL1 mutants in murine erythroleukemia (MEL) cells treated with dimethyl sulfoxide (DMSO) for 24 h. It has been reported that the DMSO treatment of MEL cells dramatically decreased the TAL1 --LSD1 interaction. 13 The expressed Flagtagged TAL1 mutants were then precipitated with Flag antibody and blotted with LSD1 antibody. While the TAL1 S172A mutant enhances the interaction with LSD1 in comparison with the WT TAL1, TAL1
D142À185 specifically loses its interaction with LSD1 ( Figure 1e ). Thus, both in vitro and in vivo data indicate that serine 172 phosphorylation of TAL1 has an important role in regulating its interaction with LSD1.
Serine 172 is critical for regulating the recruitment of LSD1, H3K4methylation and TAL1-mediated repression of p4.2 gene Next, we test whether phosphorylation of ser172 modulates erythroid progenitor differentiation by regulating TAL1 target gene transcription. To test this possibility, MEL cells expressing retroviral vectors encoded WT TAL1, TAL1 S172A or TAL1
cDNA were treated with 1.5% DMSO and then examined for erythroid differentiation by benzidine staining of the accumulation of hemoglobin. Compared with the WT TAL1 control, TAL1 S172A that mimics unphosphorylated TAL1 and increases its interaction with LSD1 consistently inhibited DMSO-induced erythroid differentiation of MEL cells (Figure 2a) . Meanwhile, the deletion of the LSD1-interacting domain in TAL1 significantly promoted erythroid differentiation ( Figure 2a ). The levels of Flag-TAL1 expression were compatible between WT and mutants as well as that of endogenous TAL1 (Figure 2b ). These data suggest that serine 172 of TAL1 regulates TAL1 directed erythroid differentiation by modulating its interaction with histone demethylase LSD1.
Given that LSD1 is an H3K4-specific demethylase and modulates transcription by altering promoter chromatin modifications, the TAL1 mutants that change its ability to recruit LSD1 may affect its target gene transcription that is important for erythroid differentiation program. To test this possibility, a chromatin immunoprecipitation (ChIP) was carried out using antibodies against LSD1 and H3K4 dimethylation in MEL cells stably expressed Flag-tagged TAL1, TAL1 S172A and TAL1 D142À185 to examine the effects of TAL1 mutants on LSD1 recruitment and promoter activity. As we expected, LSD1 interacted with the TAL1 binding sites, E box-GATA elements, at the proximal EPB4.2 (P4.2) promoter in the control and WT TAL1 transduced cells (Figures 2c  and d) . Deletion of the LSD1-interacting domain in TAL1 resulted in a significant loss of LSD1 recruitment while TAL1 S172A did not affect its interaction with LSD1 at the P4.2 promoter in undifferentiated MEL cells ( Figure 2d ). As a result, H3K4 dimethylation is significantly elevated at the P4.2 promoter and the level of p4.2 mRNA is also increased in the TAL1 D142À185 expressed MEL cells (Figures 2e and f) . Taken together, the results reveal that the serine 172 of TAL1 that can be phosphorylated by PKA regulates TAL1-dependent transcriptional activity and erythroid differentiation program by modulating its dynamic association with H3K4 demethylase LSD1.
Serine 172 of TAL1 modulates TAL1 repressive activity in T-ALL cells Activation of TAL1 is the most common gain-of-function mutation found in T-ALL patients. 22,43 --45 In T-cell leukemia, TAL1 suppresses T-cell differentiation and perturbs cell-cycle progression during the double negative T-cell stage. 28 pre-TCRa (pTa) is exclusively expressed in developing thymocytes and is an essential selection and survival signal for the development of T thymocytes. 30 ,46 E box motifs in the enhancer region of the pTa gene are required for its activation by E2A/HEB heterodimer in normal T-cell development and are occupied and repressed by TAL1 in Jurkat cells (Figure 3a) . 46 Sequence comparison showed a 70.5% identity between mouse and human pTa enhancer sequences (Supplementary Figure S1B ). We further hypothesized that the TAL1 mutants that change TAL1's ability to recruit LSD1 may affect Tcell growth by altering the transcription of TAL1 target genes such as pTa and p21 in T-cell leukemia. To test this possibility, we stably expressed Flag-tagged TAL1 and its mutants, TAL1 S172A and TAL1
D142À185 that changed the TAL1's affinity to LSD1, in T-ALL Jurkat cells (Supplementary Figure S1C) . ChIP assays were then performed in Jurkat cells that stably expressed Flag-TAL1 and its mutants using Flag, LSD1 and H3K4me2 antibodies to test the effects of mutations on LSD1 recruitment and H3K4 methylation at the pTa and p21 enhancers. Flag-tagged TAL1 and its mutants bind equally to the enhancer region of the pTa gene ( Figure 3b ). Interestingly, correlated with TAL1 binding, LSD1 is also recruited to the same region of the pTa enhancer except for the TAL1 D142À185 mutant, which lacks the LSD1-interacting domain and significantly reduces LSD1 recruitment at the enhancer ( Figure 3c ). The reduction of LSD1 recruitment was also seen at the promoter region ( Figure 3c ; see Discussion). Due to the decrease in the LSD1 recruitment, the expression of TAL1
led to an increase in H3K4me2 at the enhancers and the proximal promoters of the pTa gene ( Figure 3d ) as well as the p21 gene (Supplementary Figure S2C) , a cell cycle-dependent kinase inhibitor that blocks the cell cycle during G1 to S phase transition and is also targeted by TAL1. 15, 30 As a control, the TAL1 mutants did not affect the level of H3K4me2 at the promoter of TAL1 activated target, Runx1 (Supplementary Figure S2E) . These results suggest that LSD1-mediated epigenetic modification is important for TAL1 repressive action in leukemogenesis and the action of LSD1 may be also dependent on serine 172 phosphorylation.
PKA-mediated phosphorylation modulates TAL1 repressive activity in T-ALL cells Next, we reasoned if PKA-mediated phosphorylation of Ser172 in TAL1 modulates the recruitment of LSD1 and its repressive activity in T-ALL, PKA activator, forskolin, may relief the TAL1 repression while PKA inhibitor should enhance repression. To test this hypothesis, we first asked whether PKA inhibitor, H89, or activator, forskolin, inhibits or enhances PKA-mediated TAL1 phosphorylation in vitro, respectively. Compared with the control, the treatment of PKA inhibitor, H89 (20 mM), abolished the phosphorylation of TAL1 while PKA activator, forskolin (40 mM), enhanced it (Figure 4a ). To further test whether PKA-mediated phosphorylation contributes to the regulation of the interaction between TAL1 and LSD1, the Flag-tagged TAL1 expressed Jurkat cells were treated with PKA inhibitor H89 or PKA activator forskolin in the same concentration described above. Nuclear extracts were prepared and examined for the TAL1 --LSD1 interaction by co-immunoprecipitation assays using antibody specific to Flag (Figure 4b Figure S2B) . Thus, the data suggest that ser172 phosphorylation of TAL1 by PKA destabilizes TAL1 interaction with histone demethylase LSD1 complex in T-ALL Jurkat cells.
In addition, to test whether PKA-mediated phosphorylation of serine 172 of TAL1 regulates TAL1 transcriptional activity in T-ALL, Jurkat cells were treated with 20 and 40 mM of PKA inhibitor H89 and PKA activator forskolin for 2 h, respectively. As expected, H89, which inhibits PKA-mediated phosphorylation of TAL1 (Figure 4a ) and enhances the TAL1 --LSD1 interaction, suppresses pre-Ta (Figure 4c) . In contrast, forskolin that destabilizes the TAL1 --LSD1 interaction by activating PKA activity (Figure 4a; Supplementary Figure S2A , bottom) stimulates the expression of the pTa and the p21 genes (Figure 4c ). Although neither H89 nor forskolin affects TAL1 binding to the pre-Ta enhancer (Figure 4d ), the recruitment of LSD1 to the pTa gene is significantly impaired by the PKA activator forskolin treatment (Figure 4e) . As a consequence of the change of LSD1 recruitment, H89 inhibits H3K4 dimethylation while forskolin stimulates H3K4 methylation at the pTa gene (Figure 4f) . The similar results have also been observed in the p21 locus (Supplementary Figure S2D) . It is interesting to note that although H89 slightly enhances the LSD1 recruitment but still inhibits H3K4 dimethylation. It is possible that the TAL1 phosphorylation level is low in Jurkat cells and H89 treatment would not increase the TAL1-associated LSD1, but strengthen their interaction. It is also possible that H89 has a negative effect on TAL1's ability to recruitment co-activator such as hSET1. Nevertheless, the changes of TAL1 phosphorylation status dynamically regulate its interaction with LSD1 and the target promoter H3K4 methylation. Although TAL1 binds only to the pTa enhancer, the recruitment of LSD1 and reduction of H3K4me2 were observed in both enhancer and promoter (Figures 4d --f ) that might be due to a possible enhancer and promoter interaction during transcriptional regulation (see Discussion). Taken together, our data indicate that modulation of PKA activity regulates the dynamic interactions between TAL1 and LSD1, which then controls transcription of the TAL1 target genes during leukemogenesis.
LSD1 is required for transcriptional repression of TAL1 target genes in T-ALL cells TAL1 is frequently activated in the majority of T-ALL patients.
22,43 --45
The repressive activity of TAL1 has been linked to leukemogenesis. 21, 47 In fact, the gene expression profiling analysis of the TAL1-induced preleukemic thymocytes shows that aberrant activation of TAL1 in T cells leads to the repression of many more genes than genes being activated. 27 We then asked whether LSD1 is required for TAL1-dependent transcriptional repression in T-ALL leukemia cells. To test this hypothesis, LSD1 was knocked down in T-ALL Jurkat cells by SMART pool LSD1 siRNAs (Figure 5a ). KD of LSD1 led to a strong derepression of the TAL1 targets, pTa and p21, as well as a known LSD1 target PTEN gene (Figure 5b) , which was recently shown to be a direct TAL1 target in T-ALL cells. 48 The effects of LSD1 appear to be specific for the TAL1 repressive targets because KD of LSD1 did not affect the TAL1 activated target, Runx1, 48 and unrelated STIL genes (Figure 5b ). We further examined the TAL1 binding, LSD1 recruitment and H3K4methyla-tion at the pTa gene enhancer to test whether LSD1 is required for the inhibition of the TAL1 target genes, such as pTa and p21, in T-ALL cells. Figure 5 shows that KD of LSD1 did not affect the interaction of TAL1 with chromatin ( Figure 5c ). However, correlated with the derepression of the pTa and p21 genes (Figure 5b) , KD of LSD1 that eliminated LSD1 recruitment (Figure 5d ) increases the levels of H3K4me1 and H3K4me2 at the TAL1 bound pTa enhancer (Figures 5e and f) as well as at the p21 enhancer (Supplementary Figure S2F) . Collectively, our data demonstrate that LSD1 recruitment is required for inhibiting TAL1 target genes that are required for the T-cell development in Jurkat T-ALL cells.
LSD1 is recruited by TAL1 to repress genes required for T-cell development Next, we sought to determine whether LSD1 is recruited by TAL1 to regulate genes important for T-cell development in Jurkat cells. The cells were stably expressed a doxycycline (Dox) inducible shRNA specifically targeting the human TAL1 sequence. 48 TAL1 levels are dramatically diminished in the transduced Jurkat cells at Figure S3A) , supporting that TAL1 is required for T-cell leukemic transformation. 23 Furthermore, the loss of the colony formation may also be due to a significant increase in apoptotic cells in the Dox-induced TAL1 KD Jurkat cells (Supplementary Figure S3B, bottom blue color) . Importantly, KD of TAL1 resulted in a strong derepression of pTa, p21 and PTEN genes ( Figure 6b) . As a control, KD of TAL1 in Jurkat cells reduced its activated target Runx1 48 and did not affect unrelated STIL expression (Supplementary Figure S3C) . We therefore tested whether the loss of TAL1 leads to a decrease in LSD1 recruitment at the pTa enhancer (Figure 6c ), which may contribute to the derepression of the pTa gene in the induced KD cells (Figure 6b) . Although TAL1 and LSD1 are colocalized at the pTa enhancer in control cells (Figures 6d and e) , the recruitment of LSD1 to the enhancer is dependent on the TAL1 DNA binding because the KD of TAL1 resulted in a significant decrease in LSD1 binding at the enhancer (Figures 6d and e) . As a result of the loss of LSD1 recruitment, both H3K4me1 and H3K4me2 marks were increased at the pTa (Figures 6f and g ) and p21 (Supplementary Figures S3D  and E) enhancers, which correlate with the derepression of the pTa and p21 genes in the induced TAL1 KD Jurkat cells (Figure 6b) . The results reveal that TAL1 represses target gene transcription by recruiting LSD1 and removing H3K4 methylation marks in T-cell leukemia.
Activation of the TAL1-dependent p4.2 transcription and erythroid differentiation is associated with decreased LSD1 recruitment and increased H3K4 methylation Finally, we tested whether the dynamic interaction between TAL1 and LSD1 is functionally important for TAL1-mediated erythroid differentiation of CD34 þ HSCs. CD34 þ HSCs were differentiated into CD36 þ erythroid precursors with the addition of erythropoietin. P4.2 transcription is strongly induced in CD36 þ erythrocytes (Figure 7a) . Consistent with the induction of P4.2 expression, ChIP assay showed that although TAL1 binds equally to the P4.2 proximal promoter in CD34 and CD36 cells, LSD1 recruitment decreased by 45% at the P4.2 promoter in CD36 cells (Figure 7b) . Surprisingly, hSET1, a histone H3K4 methyltransferase, was recruited to the promoter only in CD36 þ erythroid precursors, but not in CD34 þ HSCs (Figure 7b) . Furthermore, the inhibition of PKA activity by PKA inhibitor H89 in CD34 þ HSCs blocks erythropoietin-induced differentiation and inhibits p4.2 transcription (Supplementary Figures S4A and B) . We observed a 10% decrease in CD36 þ erythroid precursor in the H89-treated cells (Supplementary Figure S4A) . Together, these data are consistent with the notion that PKA-mediated phosphorylation of TAL1 destabilizes the TAL1 and LSD1 interaction during hematopoiesis. The reduction of LSD1 recruitment and the increase in hSET1 binding strongly correlate with the elevation of H3K4me2 and H3K4me3 levels at the p4.2 promoter region upon differentiation (Figure 7c) . We further performed an unbiased genome-wide ChIP-seq analysis of H3K4 monomethyl and trimethyl H3K4 modification patterns at the p4.2 locus comparing CD34 þ HSCs to CD36 þ erythroid precursors. Correlating with the transcriptional activity of the P4.2 gene and the hSET1 recruitment (Figures 7a and b) , both H3K4 monomethylation and trimethylation are only enriched at the proximal P4.2 promoter in CD36 þ erythroid precursors but not in the P4.2 silenced CD34 þ HSCs (Figure 7d ) consistent with the ChIP data (Figure 7c) . Thus, our data suggest that the levels of H3K4 methylations have an important role in p4.2 activation during erythroid differentiation. Together, our results reveal that the dynamic regulation of H3K4 demethylase and methyltransferase, perhaps by PKA-mediated phosphorylation of TAL1, has a critical role in controlling erythroidspecific gene transcription during hematopoiesis.
DISCUSSION
As a master regulator of hematopoiesis, TAL1 transcriptional activity has been attributed to its ability to recruit transcriptional corepressors and co-activators.
10 --15 Dynamic interactions between TAL1 and coregulators result in different transcriptional consequences affecting hematopoietic cell differentiation and proliferation. TAL1 functions as an activator of erythroid differentiation programs while its repressive activity has been linked to oncogenesis in T-cell lineage. 8, 9, 21, 27, 28, 49 It has been suggested that inappropriate associations of transcription factors with histone modifying enzymes often lead to aberrant activation or repression of normal gene expression patterns and perturb cellular differentiation and proliferation that may eventually contribute to malignancies. 21, 49 How is the dynamic interaction of TAL1 with corepressors and co-activators properly modulated during hematopoiesis? What is the signal(s) that turns this molecular circuit on and off? We previously showed that TAL1 associates with histone demethylase LSD1 in erythroleukemia cells. LSD1 removes the methyl group from histone H3 lysine 4 of the TAL1 target genes and restricts TAL1 function in erythropoiesis. 13 Upon induced erythroid differentiation, LSD1 may be released from the TAL1 complex and allow it to function as an activator, presumably recruiting co-activators for activating erythroid transcription programs 21 ( Figure 7) . Although the dramatically increase in hSET1 recruitment alone may be attributed to the elevation of H3K4me2 levels at the P4.2 promoter. The PKA inhibitor H89 blocks CD34 þ HSC differentiation (Supplementary Figure S4) 50 , suggesting that CD34 þ cell differentiation in part is mediated through the activation of the PKA pathway, perhaps by regulating TAL1-associated coregulators, such as LSD1. During T-cell leukemogenesis, TAL1 and LSD1 also cooperatively inhibit the transcription of pTa, p21 and Pten genes, which have critical functions in T-cell survival, proliferation and differentiation (Figures 5 and 6 ). We further demonstrated that the dynamic interaction of TAL1 with H3K4 demethylase LSD1 is regulated by PKA-mediated serine 172 phosphorylation of TAL1 protein. A key finding of this work is that PKA signal pathway regulates TAL1 association with LSD1 in the normal erythroid differentiation program and leukemogenesis of T-cell lineages. The phosphorylation of serine 172 of TAL1 specifically destabilizes TAL1 interaction with histone demethylase LSD1 and, therefore, leads to the activation of the certain TAL1 target genes in differentiated erythroid cells or T-cell leukemia. It was reported that TAL1 is phosphorylated in vitro and in vivo by PKA. 18 Although the subcellular localization of TAL1 and its ability for the dimerization with E2A protein were not affected by this phosphorylation. The ser172 phosphorylation has a targetdependent effect on TAL1 DNA binding activity, thereby affecting transcription activities of TAL1. 18 The effect on the TAL1 and LSD1 interaction described in this report further illustrates the role of PKA-mediated phosphorylation in TAL1's function in transcriptional regulation. Taken together, these studies provide a potential explanation and underlying mechanism of how TAL1 dynamically interacts with corepressor LSD1 on certain targets in the same cells according to their differentiation stage.
TAL1 activity can be regulated by phosphorylation. Phosphorylations of Thr90 by Akt kinase and Ser122 by MAP kinase enhance transcriptional activity in TAL1. 17, 20 Interestingly, ser172 that is located within the LSD1-interacting domain was also phosphorylated by PKA kinase in vitro and in vivo. 18 In addition, we demonstrated in this report that in-vitro phosphorylation of TAL1 by PKA abolished the interaction between TAL1 and LSD1 while substitution of ser172 to Ala did not affect the interaction (Figure 1 ), indicating that phosphorylation of ser172 in TAL1 by PKA destabilizes the TAL1 ability to associate with corepressor LSD1. Consistent with the positive role of the phosphorylated TAL1, we found that ser172 phosphorylation acts as an epigenetic switch that potentiates TAL1 transcription by altering TAL1-associated histone modifying enzymes, such as LSD1, and changes H3K4 methylation marks at TAL1 target genes. It is also interesting to note that the association between TAL1 and mSin3A is regulated through the acetylation of TAL1 by the histone acetyltransferase p300/CBP-associated factor. mSin3A containing complexes repress transcription by removing the acetyl group, another active histone mark, from histone H3 and H4 tails. 11 Thus, both ser172 phosphorylation and acetylation of TAL1 destabilize different corepressors that restrict TAL1 function in hematopoietic differentiation. Cooperation between ser172 phosphorylation and lysine acetylation of TAL1 may have an important role in modulating TAL1 activity in hematopoietic proliferation and differentiation.
In addition to histone modification enzymes, corepressor ETO-2 was found in TAL1 containing multiple protein complexes. 14 --16 ETO-2 is a member of the ETO (eight-twenty-one) family of transcription repressors which are frequently involved in chromosome translocation in acute leukemia. 49 ETO-2 is recruited by TAL1 to repress erythroid-specific target gene transcription in undifferentiated erythroid progenitors. Similarly to the recruitment of LSD1, the presence of ETO-2 at the TAL1 targeted erythroid genes decreases during terminal erythroid differentiation. 16 What is the signal(s) that turns off the interaction between TAL1 and ETO-2? Does PKA-mediated phosphorylation of TAL1 also regulates this interaction? It has been reported that ETO-2 can mediate the interaction between TAL1 and Gfi-1b in erythroid cells.
14 In fact, both TAL1 and Gfi-1b interact with histone demethylase LSD1. 13, 42 In addition, ETO-2 is present in the TAL1/LSD1 complexes from biochemical purification in K562 and Jurkat cells, 13 suggesting that TAL1, ETO-2 and LSD1 might present in the same repressor complex to inhibit erythroid differentiation program. However, it remains to be further determined whether PKA signaling also regulates TAL1/ETO-2 interaction in erythropoiesis.
What are the roles of LSD1 in normal versus malignant hematopoiesis? Hematopoiesis is a complex process that involves transcription factors committing and differentiating HSCs into progenitor cells that progressively restrict their proliferation potential. The process of hematopoietic cell differentiation is frequently perturbed in leukemia. TAL1 is a master regulator of this process whose activity modulates hematopoietic cell proliferation and differentiation. In this regard, LSD1 controls hematopoietic differentiation by associating with hematopoieticspecific transcription factor TAL1 and Gfi-1B. 13, 42 TAL1 and LSD1 interaction limits the differentiation of erythroid progenitor cells. 13, 42 Inhibiting the interaction between TAL1 and LSD1 is critical in allowing erythroid progenitors to differentiate. We demonstrated here that this process is regulated by PKA-mediated phosphorylation. During erythroid differentiation, we observed that hSET1 is recruited to the p4.2 gene when LSD1 is released from the promoter (Figure 7b ). hSET1 recruitment contributes to H3K4 methylation of the promoter and the activation of the p4.2 gene in CD36 erythroid precursors (Figure 7) . It remains to be determined whether hSET1 is recruited by TAL1 or other erythroid-specific transcription factors. Regardless, our data suggest that the interplay between signal transduction pathways and histone modifying enzymes may have a critical role in controlling chromatin structure and the timing of hematopoietic programs.
In contrast to normal hematopoiesis, TAL1 was shown to inhibit pre-Ta and CD4 genes in T-cell leukemia, 28, 30, 46 which have a central role in the transition of thymocytes from the double negative (DN) to the double positive (DP) stage during T-cell development. The repressive action of TAL1 requires the recruitment of LSD1 (Figures 5 and 6 ), as well as ETO2 and mSin3A. 10,13 --15,30 Although TAL1 only recognizes the pTa enhancer region, binding of TAL1 at enhancer apparently modulates the recruitment of LSD1 and demethylase activity at the pTa proximal promoter, therefore, efficiently represses pTa expression in T-ALL cells (Figures 3 and 4) . It is interesting to note that transcription factor binding at enhancer is able to control proximal promoter activity by modulating promoter chromatin modifications in the GATA-2 and b-globin loci. 51, 52 Long-range chromatin looping has been shown to mediate efficient communication between enhancers and promoters. 53 In this regard, enhancer occupied TAL1 may form a repressive chromatin loop to control the pTa promoter activity, perhaps, mediated by LSD1. The notion is supported by the evidence that LSD1 is required for nuclear receptor-mediated epigenetic remodeling of a large chromosomal region through an LSD1-dependent interchromatin or intrachromatin interaction. 54, 55 However, we could not rule out that possibility that the recruitment of LSD1 to the pTa promoter is mediated in part through other transcription factors or mechanisms.
On the other hand, TAL1 also activates a variety of genes affecting T-cell survival and growth, including CDK6, Runx1 and NKX3.1. 23, 48, 56 Given that PKA phosphorylation regulates the TAL1 --LSD1 interaction in T-ALL Jurkat cells (Figures 3 and 4) , it will be interesting to know if PKA phosphorylation of TAL1 could facilitate TAL1's ability to recruit co-activators during leukemogenesis. Although it is unknown whether a co-activator(s) is involved in the TAL1-mediated activation of CDK6 and NKX3.1 genes in leukemogenesis, our study identified an underlying mechanism by which phosphorylation regulated demethylase LSD1 recruitment controls the timing of erythroid differentiation and oncogenesis of T-cell leukemia.
MATERIALS AND METHODS
Cell lines, virus-mediated transduction and siRNA KD MEL and Jurkat cells were maintained as described. 10 For MEL differentiation, 2 Â 10 5 MEL cells/ml were incubated with 1.5% DMSO for specific time periods as indicated. The expression of hemoglobin was visualized by benzidine reagent (Sigma, St Louis, MO, USA) as described previously. 57, 58 The fraction of hemoglobin-expressing cells was determined from counts of 200 cells in three independent experiments. Human CD34 þ and CD36 þ cells were enriched through positive immune-selection by flow cytometer and cultured according to manufacturer's instruction (Stem Cell Technologies, Vancouver, BC, Canada). Plasmid constructs, retrovirusmediated transduction and siRNA-mediated KD were described previously. 13 The LSD1 KD in Jurkat cells was carried out by transfecting 40 pmol SMART pool LSD1 siRNAs (Cat#:M-009223-00-0050, Dharmacon RNAi Technologies, Lafayette, CO, USA) using Nucleofector II. The cells were analyzed in 48 h post transfection. The siRNA sequences are available in the Supplementary information.
Site-directed mutagenesis and in vitro phosphorylation
Oligonucleotide-mediated mutagenesis of ser172 to Ala or ser172 to Asp was performed on pGex-5X-Tal1 according to manufacturer's instructions Phosphorylation regulates oncogenic TAL1 activity Y Li et al (Stratagene, La Jolla, CA, USA) and verified by DNA sequencing. For in-vitro phosphorylation, 500 ng of the purified GST or GST --TAL1 fusion proteins was phosphorylated by 100 ng of the purified PKA catalytic subunit (65 kDa; Sigma) in a 50 ml reaction volume containing 50 mM Tris--HCl, pH 7. GST pulldown and in vitro transcription and translation
The GST-pulldown assay was performed as described. 12 Briefly, GST fusion proteins were synthesized in the BL-21 strain of E. coli and purified on glutathione-sepharose 4B following manufacturer's instruction (GE Healthcare, Piscataway, NJ, USA). Equal amount of GST proteins was incubated with [ 
RNA isolation and quantitative RT --PCR
Total RNA was prepared by using the SV total RNA isolation kit according to manufacturer's instruction (Promega, Madison, WI, USA). A total of 1.5 mg RNA was treated with RNAse-free DNase I and then reverse transcribed by using the Superscript II reverse Transcriptase, following manufacturer's suggestion (Invitrogen, Grand Island, NY, USA). The quantity of cDNA was determined by qPCR analysis using a MyiQ Single-Color Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). Primer sequences and conditions for qPCR are available upon request.
Co-immunoprecipitation and ChIP
The TAL1 complexes were immunoprecipitated from prepared nuclear extracts using Flag-or TAL1-specific antibodies. The immunocomplexes were resolved in SDS --PAGE and analyzed by western blotting analysis. TAL1 antibody was generated in rabbits by using human TAL1 fragments (aa 301 --317; aa 276 --289) as antigens.
Real-time PCR quantitative ChIP assays were carried out as described 57 using indicated antibodies with slight modifications. The fold difference was determined by the following equation: 2
Ct(IP)-Ct(Ref)
. LSD1, H3K4me1 and H3K4me2 antibodies were purchased from Millipore (Lake Placid, NY, USA). hSET1 antibody was purchased from Bethyl Laboratory (Montgomery, TX, USA). TAL1 and HDAC1 antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
ChIP-Seq
Primary human CD34 þ cells were isolated and differentiated to CD36 þ cells as described. 32 ChIP-Seq assays were performed as described. Sequence reads of 25 bp were obtained, mapped to human genome (hg18) and processed as described previously. 59 The sequence reads have been deposited in the NCBI Short Read Archive (GSE12646). The BED files can be downloaded from the website (http://dir.nhlbi.nih.gov/papers/lmi/ epigeneomes/hghscmethylation.html).
